Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19.

Published in: British journal of clinical pharmacology (2022)

This meta-analysis showed that the use of three doses of molnupiravir (200, 400 and 800 mg) is safe for COVID-19 patients. Further research is needed to confirm the present findings.

Keyphrases

systematic review
sars cov
meta analyses
loop mediated isothermal amplification
randomized controlled trial
sensitive detection